ArticleMedicine2026
Exploring the mechanisms of Cangfu Daotan decoction in homotherapy for heteropathy of polycystic ovary syndrome, insulin resistance, infertility, and obesity.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study aims to explore the mechanism of Cangfu Daotan decoction (CFDT) in treating polycystic ovary syndrome, insulin resistance, obesity, and infertility with homotherapy for heteropathy based on network pharmacology methods. The active components and corresponding protein targets of CFDT were identified through a systematic screening of the Traditional Chinese Medicine Systems Pharmacology database, while disease-associated targets were retrieved from OMIM, Genecards, and DrugBank databases. Common targets were derived from Venn analysis and utilized to construct a protein-protein interaction network via STRING and Cytoscape 3.8.0, through which core targets were identified. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway assessment were subsequently performed on these key targets using R 4.1.1. Molecular docking simulations were finally conducted to evaluate binding interactions between pivotal bioactive compounds and the identified core targets. A total of 151 active ingredients, 238 drug targets and 2722 disease targets were screened. Among them, quercetin, kaempferol, luteolin, and wogonin are the main active ingredients. TP53, AKT1, STAT3, IL6, and HSP90AA1 are the core therapeutic targets. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis screened 178 pathways, including lipid and atherosclerosis and advanced glycation end product (AGE)-receptor for AGE signal pathways in diabetes complications. Gene Ontology functional enrichment analysis yielded 2423 Gene Ontology entries, mainly involving biological processes including heterologous stimulation, lipopolysaccharide response, oxidative stress, glandular development, as well as cellular composition including membrane rafts and vesicles, and molecular functions including DNA binding transcription factor binding and cytokine activity. Molecular docking shows that the active ingredients of CFDT have good affinity for core disease targets. Molecular docking confirmed strong binding affinity between key compounds and targets. It is preliminarily revealed that the main active ingredients of CFDT are quercetin, kaempferol, luteolin and wogonin, which may improve polycystic ovary syndrome, insulin resistance, obesity, and infertility by regulating lipid and atherosclerosis and AGE-receptor for AGE signal pathways in diabetes complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.